Vinpocetine

Country of origin: Russia, Biocom (Stavropol), Gedeon Richter A.O. (Hungary), Kanonpharma Production (Russia), Covex SA (Spain), Makiz-Pharma (Russia), Mir-Pharm (Russia), Moskhimfarmpreparaty im. ON THE. Semashko (Russia), Obolenskoye Pharmaceutical Enterprise (Russia), Northern Star (Russia).

Pharmaceutical group: Drugs that improve cerebral circulation.

Manufacturers: ALSI Pharma (Russia), Biocom (Stavropol, Russia), Gedeon Richter A.O. (Hungary), Kanonpharma Production (Russia), Covex SA (Spain), Makiz-Pharma (Russia), Mir-Pharm (Russia), Moskhimfarmpreparaty im. ON THE. Semashko (Russia), Obolenskoe pharmaceutical enterprise (Russia).

International name: Vinpocetine.

Synonyms: Bravinton, Vero-Vinpocetine, Vinpoton, Vinpocetine-Akos, Vinpocetine-Akri, Vinpocetine-Darnitsa, Vinpocetine-NS, Vinpocetine-Rivo, Vinpocetine-Rivo 5, Vinpocetine-Rivofarm, Vinpocetine-Sar, Vincetine, Cavinton, Cavinton Forte, Telektol.

Dosage forms: tablets 5 mg, solution for injection 0.5%, concentrate for the preparation of infusion solution 5 mg/ml.

Composition: Active substance - vinpocetine.

Indications for use: Acute and chronic disorders of cerebral circulation (stroke, brain injury, atherosclerotic changes in cerebral vessels), memory impairment, movement disorders, dizziness, headache, spasm of cerebral vessels, arteriolosclerotic and angiospastic changes in the retina and choroid, arterial and venous thrombosis blood vessels of the eye, age-related, vascular or toxic (drug-induced) hearing disorders, vegetative manifestations of menopausal syndrome.

Contraindications: Severe heart rhythm disturbances, high functional class angina, pregnancy, lactation.

Side effects: Hypotension, tachycardia, extrasystole, increased duration of ventricular electrical systole; with parenteral administration: dizziness, feeling of heat, redness of the face, thrombophlebitis at the injection site.

Interaction: Increases the risk of hemorrhagic complications during heparin therapy.

Overdose: In case of intoxication, gastric lavage, intake of activated carbon and symptomatic treatment are recommended.

Special instructions: For patients with cardiac pathology, vinpocetine should not be administered intravenously due to the risk of developing arrhythmia, including ventricular fibrillation. Prescribe with caution for hemorrhagic stroke (only after completion of the acute phase).

Literature:

1. Encyclopedia of drugs 2002
2. Directory "Medicines" M.D. Mashkovsky 14th edition.
3. Instructions for use of the drug Vinpocetine, approved by the Federal Code of the Ministry of Health of the Russian Federation on October 9, 2003.